Gliatech floats at $9.50 a share:
This article was originally published in Clinica
At $9.50 a share, US company Gliatech lowered the price of shares in its initial public offering from the $11 assumed in the prospectus (see Clinica No 676, p 12). Selling 2.3 million shares, Gliatech raised around $20 million to be used for the manufacturing and marketing of the company's Adcon anti-adhesion products in Europe and clinical trials in the US and Europe
You may also be interested in...
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Lilly has launched a similar antibody product, but demand is expected to outpace supply for the foreseeable future.